Ertugliflozin → Decreased appetite — Audit-grade candidate (class scan)

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Ertugliflozin → Decreased appetite — Audit-grade candidate (class scan)

Drug: ertugliflozin · AE: Decreased appetite

Discovered via class scan of SGLT2 inhibitors. PRR = 2.14, n = 30 cases.

Disproportionality

PRR: 2.1398543954133546
Yates χ²: n/a
Cases (case-drug + AE): n = 30
Verdict: PASSES_ALL_GATES — PRR=2.14 (95% CI 1.50–3.05), n=30 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: 311d95a991bd1ac6ca563454b5e3088432028b25